Johannes Oldenburg Selected Research

glutamyl carboxylase (gamma-glutamyl carboxylase)

1/2022	The Role of GRP and MGP in the Development of Non-Hemorrhagic VKCFD1 Phenotypes.
1/2021	GGCX mutations show different responses to vitamin K thereby determining the severity of the hemorrhagic phenotype in VKCFD1 patients.
10/2014	Bleeding and non-bleeding phenotypes in patients with GGCX gene mutations.
9/2006	Founder mutation Arg485Pro led to recurrent compound heterozygous GGCX genotypes in two German patients with VKCFD type 1.
8/2004	Compound heterozygous mutations in the gamma-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Johannes Oldenburg Research Topics

Disease

80	Hemophilia A (Haemophilia) 05/2022 - 06/2002
65	Hemorrhage 04/2022 - 11/2002
16	Thrombosis (Thrombus) 01/2022 - 03/2006
9	Hemophilia B (Haemophilia B) 02/2022 - 09/2003
8	Thrombophilia 01/2022 - 08/2012
7	Infections 03/2021 - 01/2009
6	COVID-19 09/2022 - 03/2021
6	von Willebrand Diseases (von Willebrand's Disease) 01/2022 - 07/2004
5	Venous Thromboembolism 05/2022 - 01/2005
5	Type 3 von Willebrand Disease 03/2022 - 11/2019
5	1 Combined Deficiency Of Vitamin K-Dependent Clotting Factors 01/2022 - 08/2004
5	Thrombotic Microangiopathies 05/2021 - 01/2017
5	Type 2 Combined Deficiency Of Vitamin K-Dependent Clotting Factors 08/2015 - 02/2004
5	Coumarin Resistance 10/2013 - 02/2004
4	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022 - 01/2005
3	Wounds and Injuries (Trauma) 01/2022 - 01/2014
3	Joint Diseases (Joint Disease) 11/2021 - 03/2015
3	Thrombocytopenia (Thrombopenia) 10/2021 - 10/2016
3	Metrorrhagia (Spotting) 05/2021 - 01/2017
3	Neoplasms (Cancer) 01/2021 - 01/2019
3	Hypersensitivity (Allergy) 06/2018 - 02/2008
3	Autoimmune Diseases (Autoimmune Disease) 01/2018 - 04/2006
3	Factor XIII Deficiency 02/2017 - 06/2010
3	Activated Protein C Resistance (APC Resistance) 01/2017 - 01/2014
2	Mast Cell Activation Disorders (Mast-Cell Disease) 08/2021 - 01/2015
2	Inborn Genetic Diseases (Disease, Hereditary) 01/2021 - 06/2005
2	Vitamin K Deficiency 01/2021 - 10/2014
2	Thromboembolism 01/2017 - 08/2015
2	Hydatidiform Mole (Molar Pregnancy) 01/2015 - 10/2014
2	Stomach Neoplasms (Stomach Cancer) 01/2015 - 10/2014
2	Fetofetal Transfusion (Twin Transfusion Syndrome) 03/2014 - 09/2011
2	Atherosclerosis 01/2014 - 06/2007
2	Hepatitis C 05/2011 - 06/2007
2	Intracranial Aneurysm (Cerebral Aneurysm) 06/2006 - 05/2003

Drug/Important Bio-Agent (IBA)

58	Factor VIII (Coagulation Factor VIII)IBA 05/2022 - 06/2002
23	Blood Coagulation Factors (Coagulation Factor)IBA 04/2022 - 11/2002
18	Vitamin K FDA Link 04/2022 - 02/2004
14	Thrombin FDA Link 05/2022 - 05/2012
14	emicizumabIBA 01/2022 - 01/2017
13	AnticoagulantsIBA 05/2022 - 02/2004
13	Proteins (Proteins, Gene)FDA Link 02/2022 - 01/2004
12	von Willebrand FactorIBA 01/2022 - 10/2012
10	AntibodiesIBA 05/2022 - 04/2006
10	Factor IX (Coagulation Factor IX)FDA LinkGeneric 02/2022 - 09/2003
9	Protein CIBA 01/2022 - 11/2002
8	Prothrombin (Factor II)IBA 05/2021 - 01/2017
6	Factor XIII (Coagulation Factor XIII)IBA 05/2019 - 06/2010
5	glutamyl carboxylase (gamma-glutamyl carboxylase)IBA 01/2022 - 08/2004
5	Heme (Haem)IBA 09/2021 - 01/2019
5	AntigensIBA 01/2020 - 01/2004
5	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 09/2011
4	VaccinesIBA 09/2022 - 06/2021
4	Hemostatics (Antihemorrhagics)IBA 08/2021 - 01/2016
4	AntithrombinsIBA 01/2018 - 08/2011
4	Antiviral Agents (Antivirals)IBA 01/2018 - 01/2009
4	AutoantibodiesIBA 02/2014 - 04/2009
4	coumarinIBA 11/2008 - 02/2004
3	RivaroxabanIBA 05/2022 - 01/2020
3	apixabanIBA 05/2022 - 01/2020
3	Messenger RNA (mRNA)IBA 01/2022 - 04/2006
3	Heparin (Liquaemin)FDA LinkGeneric 06/2021 - 01/2015
3	Pharmaceutical PreparationsIBA 01/2021 - 09/2007
3	Warfarin (Coumadin)FDA LinkGeneric 01/2021 - 02/2004
3	Platelet Membrane GlycoproteinsIBA 01/2020 - 09/2011
3	recombinant factor VIII N8IBA 01/2019 - 01/2017
3	nonacog beta pegolIBA 11/2018 - 12/2014
3	Protein SIBA 01/2017 - 11/2002
3	Immunoglobulin G (IgG)IBA 01/2016 - 11/2008
3	Vitamin K Epoxide ReductasesIBA 10/2014 - 09/2006
3	N- methyl- N- (1- phenylethyl)- 2- propynylamineIBA 02/2014 - 12/2009
3	EnzymesIBA 10/2013 - 06/2006
3	Interleukin-10 (Interleukin 10)IBA 04/2010 - 04/2006
2	RNA (Ribonucleic Acid)IBA 03/2022 - 05/2021
2	AlbuminsIBA 02/2022 - 01/2016
2	concizumabIBA 01/2022 - 11/2019
2	Matrix Gla ProteinIBA 01/2022 - 10/2014
2	COVID-19 VaccinesIBA 01/2022 - 06/2021
2	simoctocog alfa (Nuwiq)IBA 11/2021 - 01/2019
2	6-pyruvoyltetrahydropterin synthase (PTPS)IBA 01/2021 - 01/2019
2	Monoclonal AntibodiesIBA 01/2021 - 12/2019
2	factor IX Fc fusion proteinIBA 11/2020 - 01/2017
2	factor VIII-Fc fusion proteinIBA 05/2020 - 01/2016
2	MicroRNAs (MicroRNA)IBA 01/2020 - 01/2020
2	Antiphospholipid AntibodiesIBA 01/2020 - 05/2012
2	Factor IXa (Coagulation Factor IXa)IBA 12/2019 - 01/2017
2	Interleukin-6 (Interleukin 6)IBA 12/2018 - 01/2012
2	Immunoglobulins (Immunoglobulin)IBA 02/2015 - 12/2009
2	Biological ProductsIBA 10/2014 - 06/2007
2	Neutralizing AntibodiesIBA 09/2013 - 02/2013
2	Phosphotransferases (Kinase)IBA 09/2013 - 07/2007
2	Antidepressive Agents (Antidepressants)IBA 08/2011 - 08/2010
2	CCR5 Receptors (CCR5 Receptor)IBA 01/2009 - 01/2009
1	thiamine triphosphorate (TTP)IBA 01/2022

Therapy/Procedure

28	Therapeutics 01/2022 - 09/2003
3	Transcatheter Aortic Valve Replacement 10/2021 - 10/2016
3	Injections 01/2019 - 01/2017
2	Conservative Treatment 11/2021 - 03/2017
2	Immunotherapy 01/2021 - 01/2021
1	Ligation 03/2022
1	Orthopedic Procedures 01/2022